Roche to increase payroll in Switzerland by 1.7 percent
Basel, 26 November 2013
Roche is increasing the payroll for its 11,000-plus workforce in Switzerland by 1.7 percent with effect from 1 April 2014. This latest increase recognises the great commitment of the workforce in the face of the challenging market environment in Europe and Switzerland. Moreover, the award takes account of market salaries and wages for comparable employment and increases in the cost of living.
To reach an agreement on the adjustment of the 2014 payroll, negotiations were held at Roche over the last few weeks with the Roche Employees Association (AVR) and the Roche Basel Works Council (AKR). The result announced today was endorsed by all parties following fair, focused and constructive negotiations.
The 1.7 percent payroll increase will be used to calculate the total amount available to managers for distribution to their staff in the form of individual, performance-based salary increases as of 1 April 2014.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.